These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31448442)

  • 21. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
    Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
    Bishop JA; Yonescu R; Batista D; Begum S; Eisele DW; Westra WH
    Hum Pathol; 2013 Oct; 44(10):1982-8. PubMed ID: 23773480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
    Urano M; Nagao T; Miyabe S; Ishibashi K; Higuchi K; Kuroda M
    Hum Pathol; 2015 Jan; 46(1):94-103. PubMed ID: 25456394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Fine-Needle Aspiration Cytology in Diagnosing Secretory Carcinoma of Salivary Gland: A Systematic Review and Meta-Analysis.
    Kala PS; Gupta M; Thapliyal N
    Acta Cytol; 2024; 68(2):83-106. PubMed ID: 38228123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.
    Guilmette J; Dias-Santagata D; Nosé V; Lennerz JK; Sadow PM
    Hum Pathol; 2019 Jan; 83():50-58. PubMed ID: 30130630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
    Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
    Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Approaches for Salivary Gland Tumors with Secretory and Microcystic Features.
    Woo HY; Choi EC; Yoon SO
    Head Neck Pathol; 2018 Jun; 12(2):237-243. PubMed ID: 29139086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New developments in molecular diagnostics of carcinomas of the salivary glands: "translocation carcinomas"].
    Skálová A; Šteiner P; Vaneček T
    Cesk Patol; 2016; 52(3):139-45. PubMed ID: 27526014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland.
    Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J
    Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
    Lassche G; van Engen-van Grunsven ACH; van Hooij O; Aalders TW; Am Weijers J; Cocco E; Drilon A; Hoischen A; Neveling K; Schalken JA; Verhaegh GW; van Herpen CML
    Oral Oncol; 2023 Feb; 137():106297. PubMed ID: 36610231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
    Boon E; Valstar MH; van der Graaf WTA; Bloemena E; Willems SM; Meeuwis CA; Slootweg PJ; Smit LA; Merkx MAW; Takes RP; Kaanders JHAM; Groenen PJTA; Flucke UE; van Herpen CML
    Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.
    Zhao M; Yin M; Kuick CH; Chen H; Aw SJ; Merchant K; Ng EHQ; Gunaratne S; Loh AHP; Gu W; Tang H; Chang KTE
    Histopathology; 2020 Oct; 77(4):611-621. PubMed ID: 32590884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
    Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers.
    Kawahara A; Taira T; Abe H; Takase Y; Kurita T; Sadashima E; Hattori S; Imamura I; Matsumoto S; Fujisaki H; Sueyoshi K; Akiba J; Kage M
    Cancer Cytopathol; 2015 Oct; 123(10):603-11. PubMed ID: 26252941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.